Subscribe to Newsletter

Standards & Regulation

Business & Regulation Advanced Medicine

We Need to Talk About CRISPR

| 4 min read

Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.

Business & Regulation Digital Technologies

Forecasting Medicine Use and Controlling Supply Chains

| Tim Tinnel | 3 min read

The role of digital technologies in optimizing traceability in pharmaceutical supply chains.

Business & Regulation Standards & Regulation

GSK’s Flovent Strategy Under Federal Scrutiny?

| Rob Coker | 2 min read

US Senator Elizabeth Warren calls for a federal investigation into GSK and its discontinuation of Flovent HFA

Manufacture Facilities

FDA Warning Letters: March 2025 Edition

| Stephanie Vine | 3 min read

Indian CDMO denies manufacturing drug, contract testing lab pulled up for deficiencies, and lessons learned from Sanofi’s warning letter.

Business & Regulation Business Practice

Biden’s Legacy; Trump’s Agenda: Part 2

| 7 min read

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

Business & Regulation Business Practice

Biden’s Legacy; Trump’s Agenda: Part 1

| 10 min read

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

Business & Regulation Profession

Sitting Down With... Moncef Slaoui

| 5 min read

The career path of Moncef Slaoui has resulted in billions of doses of lifesaving vaccines. Here he shares his story.

Business & Regulation Standards & Regulation

UK Launches Seven New Centres for Regulatory Science and Innovation

| Stephanie Vine | 3 min read

A regulatory science push in the UK includes centres for digital transformation, AI and more.

Business & Regulation Standards & Regulation

RFK Jr’s Speech Leaks: Vaccines, Autism, and Chronic Illness

| Stephanie Vine | 3 min read

Robert F Kennedy Jr’s recent speech suggests that investigations into childhood vaccines and over-medication could be on the cards.

Business & Regulation Standards & Regulation

AMF’s 2026 AMR Strategy, Revealed

| Rob Coker | 3 min read

The Access to Medicine Foundation has developed the 2026 AMR Benchmark to recognize and promote urgency in the ongoing AMR challenge.


Latest White Papers

Overcoming the challenges of nitrosamine impurities in drugs

| Contributed by Thermo Fisher Scientific

HRAM LC-MS method for the determination of nitrosamine impurities in drugs

| Contributed by Thermo Fisher Scientific

LC-MS/MS method for the quantification of 10 nitrosamine impurities in metformin

| Contributed by Thermo Fisher Scientific

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

All White Papers

Sister Publications

You might be interested in our Sister Publications:

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register